Cleo Diagnostics Limited. ASX.COV
PIONEERING THE TRANSFORMATION OF OVARIAN CANCER DETECTION
Cleo Diagnostics shares its updated June 2025 corporate presentation outlining the Company's strategy and progress on "Pioneering the Transformation of Ovarian Cancer Detection."
The clinical unmet need for a screening solution for Ovarian Cancer is urgent.
Critically, no effective screening test currently exists, with the only way to definitively diagnose Ovarian Cancer being after surgery.
51% of women continue to die within 5 years of an Ovarian Cancer diagnosis. That’s 6 times higher than for Breast Cancer which has a mortality rate of only 8%.
CLEO’s disruptive patented technology offers superior performance to current clinical tests with the Company advancing its plans to address a critical unmet need on a global scale.
